Jaime P. Almandoz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jaime P. Almandoz has a total of 209 co-authors. Here are the top co-authors by number of shared publications:
- Sarah E. Messiah
Department of Epidemiology, Peter O’Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
16 shared publications - Luyu Xie
Peter O’Donnell Jr. School of Public Health, Department of Health Data Science and Biostatistics, Quantitative Biomedical Research Center, The University of Texas Southwestern Medical Center, Dallas, USA
12 shared publications Jeffrey N. Schellinger
Department of Pediatrics UT Southwestern Medical Center Dallas Texas USA
9 shared publications- Matthew Sunil Mathew
The University of Texas Southwestern Medical Center, Dallas, USA
8 shared publications - Ildiko Lingvay
Department of Internal Medicine/Endocrinology UT Southwestern Medical Center Dallas Texas USA
6 shared publications M. Sunil Mathew
University of Texas Southwestern Medical Center, Peter O’Donnell Jr School of Public Health, Dallas, USA
6 shared publications
Latest Publications
- Open Access
- 9 November 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
Screening for Nutritional Risk in Adults Receiving Obesity Treatment: A Systematic Literature Review of Available Tools and Identification of Conceptual Gaps
Aims: Identify nutrition screening tools used in obesity research and qualitatively assess their appropriateness for evaluating nutritional risk in adults receiving obesity treatment, including with obesity management medications (OMMs) in outpatient clinical settings. Materials and Methods: A systematic review of MEDLINE and Embase (29‐January‐2026) along with relevant conference websites (22‐March‐2026) targeted published studies in English of non‐hospitalized adults with obesity or overweight that used a screening tool for nutritional risk (inadequate dietary intake and/or undernutrition). Studies were manually reviewed and summarized to identify tools. Identified tools were obtained and considered for practical use in outpatient settings (e.g., length, complexity). Practical tools were qualitatively assessed for capture of clinically‐informed nutritional risk concepts in obesity treatment (e.g., weight loss, energy intake and gastrointestinal symptoms). Results: Sixteen studies met inclusion criteria and were summarized. Semi‐quantitative food frequency questionnaires ( n = 11) and an unavailable nutrition performance questionnaire ( n = 1) did not meet practical considerations. Three tools were qualitatively assessed: International Federation of Gynaecology and Obstetrics (FIGO) Nutrition Checklist, Simplified Nutritional Appetite Questionnaire (SNAQ) and Rapid Eating Assessment for Participants–Short Form (REAP‐S). Concepts relevant to nutritional risk with obesity treatment were not adequately captured by these identified tools. Notable missing concepts included weight loss, fluid intake, gastrointestinal symptoms, history of bariatric surgery and comorbid conditions. Conclusions: Identified tools did not capture key concepts for assessing nutritional risk in adults receiving obesity treatment. Thus, development of new nutrition screening tools is needed to capture these concepts in ways that are actionable for clinicians in general outpatient settings.
- 9 November 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
Open AccessScreening for Nutritional Risk in Adults Receiving Obesity Treatment: A Systematic Literature Review of Available Tools and Identification of Conceptual Gaps
Aims: Identify nutrition screening tools used in obesity research and qualitatively assess their appropriateness for evaluating nutritional risk in adults receiving obesity treatment, including with obesity management medications (OMMs) in outpatient clinical settings. Materials and Methods: A systematic review of MEDLINE and Embase (29‐January‐2026) along with relevant conference websites (22‐March‐2026) targeted published studies in English of non‐hospitalized adults with obesity or overweight that used a screening tool for nutritional risk (inadequate dietary intake and/or undernutrition). Studies were manually reviewed and summarized to identify tools. Identified tools were obtained and considered for practical use in outpatient settings (e.g., length, complexity). Practical tools were qualitatively assessed for capture of clinically‐informed nutritional risk concepts in obesity treatment (e.g., weight loss, energy intake and gastrointestinal symptoms). Results: Sixteen studies met inclusion criteria and were summarized. Semi‐quantitative food frequency questionnaires ( n = 11) and an unavailable nutrition performance questionnaire ( n = 1) did not meet practical considerations. Three tools were qualitatively assessed: International Federation of Gynaecology and Obstetrics (FIGO) Nutrition Checklist, Simplified Nutritional Appetite Questionnaire (SNAQ) and Rapid Eating Assessment for Participants–Short Form (REAP‐S). Concepts relevant to nutritional risk with obesity treatment were not adequately captured by these identified tools. Notable missing concepts included weight loss, fluid intake, gastrointestinal symptoms, history of bariatric surgery and comorbid conditions. Conclusions: Identified tools did not capture key concepts for assessing nutritional risk in adults receiving obesity treatment. Thus, development of new nutrition screening tools is needed to capture these concepts in ways that are actionable for clinicians in general outpatient settings.
- Open Access
- 9 November 2026
- Published by Wiley in Obesity Science & Practice
- Vol. 12 (6)
Association Between Peak Body Mass Index and Experienced Weight Stigma Among Adults With Obesity
Background: Experienced weight stigma (WS) is associated with negative health and psychosocial outcomes; however, the association of lifetime peak body mass index (BMI) with experienced WS remains unclear. This study examines the association between peak BMI and experienced WS. Methods: Cross‐sectional survey data from 794 patients in an academic obesity medicine program were analyzed. Experienced WS was assessed using the Stigmatizing Situations Inventory—Brief and was examined as a continuous variable. Multivariable linear regression analysis performed the association between peak BMI and experienced WS, adjusting for demographics and bariatric surgery (MBS) history. Results: Participants (mean age: 56.2 years, 86.3% female) had a mean peak BMI of 44.3 kg/m 2 . More frequent experienced WS was more prevalent in those with peak BMI ≥ 40 kg/m 2 versus < 40 kg/m 2 (58.5% vs. 34.1%, p < 0.001). After adjustment, per‐unit increase in peak BMI was associated with a 0.54 experienced WS score increase ( = 0.54; 95% CI: 0.43, 0.65; p < 0.001). MBS history was associated with increased experienced WS score, while older age and Non‐Hispanic Black were associated with lower WS score. Conclusion: Increasing peak BMI is associated with higher experienced WS scores, independent of current BMI. Clinicians should consider weight history to identify at‐risk individuals and inform stigma‐reducing interventions.
- 9 November 2026
- Published by Wiley in Obesity Science & Practice
- Vol. 12 (6)
Open AccessAssociation Between Peak Body Mass Index and Experienced Weight Stigma Among Adults With Obesity
Background: Experienced weight stigma (WS) is associated with negative health and psychosocial outcomes; however, the association of lifetime peak body mass index (BMI) with experienced WS remains unclear. This study examines the association between peak BMI and experienced WS. Methods: Cross‐sectional survey data from 794 patients in an academic obesity medicine program were analyzed. Experienced WS was assessed using the Stigmatizing Situations Inventory—Brief and was examined as a continuous variable. Multivariable linear regression analysis performed the association between peak BMI and experienced WS, adjusting for demographics and bariatric surgery (MBS) history. Results: Participants (mean age: 56.2 years, 86.3% female) had a mean peak BMI of 44.3 kg/m 2 . More frequent experienced WS was more prevalent in those with peak BMI ≥ 40 kg/m 2 versus < 40 kg/m 2 (58.5% vs. 34.1%, p < 0.001). After adjustment, per‐unit increase in peak BMI was associated with a 0.54 experienced WS score increase ( = 0.54; 95% CI: 0.43, 0.65; p < 0.001). MBS history was associated with increased experienced WS score, while older age and Non‐Hispanic Black were associated with lower WS score. Conclusion: Increasing peak BMI is associated with higher experienced WS scores, independent of current BMI. Clinicians should consider weight history to identify at‐risk individuals and inform stigma‐reducing interventions.
- 11 October 2026
- Published by Wiley in Obesity Reviews
- p. e70228
The Power of Two: Harnessing Dual Glucagon and Incretin Signaling for Treatment of Obesity and Metabolic Dysfunction–Associated Steatohepatitis—A Narrative Review with a Translational Focus
A resurgence in glucagon research has repositioned this pancreatic hormone as a promising target in the treatment of obesity and related metabolic disorders. Glucagon is classically known for contributing to glucose homeostasis, but emerging evidence points to a much wider role in metabolism, including energy balance and liver health. These findings are fueling attempts to understand how to leverage glucagon signaling to treat obesity and metabolic dysfunction–associated steatohepatitis (MASH). Due to potential hyperglycemic effects of glucagon signaling, most investigational compounds are dual agonists of both the glucagon and glucagon‐like peptide‐1 (GLP‐1) receptors to harness the antihyperglycemic and anorectic effects of the latter hormone, analogs of which such as semaglutide are already proven to be potent obesity medications. Glucagon receptor/GLP‐1 receptor dual agonists reduce food intake, decrease hepatic fat, and increase energy expenditure in animal models of obesity and MASH. In early clinical trials, some dual agonists substantially reduced body weight, hepatic steatosis, and hepatic fibrosis. Whether they are more effective than GLP‐1 receptor mono‐agonists remains to be established in definitive head‐to‐head studies. The precise balance between glucagon and GLP‐1 signaling within individual compounds appears important for overall therapeutic effects—including glycemic control, which worsened with some dual agonists. However, the two most clinically advanced compounds—mazdutide (approved for chronic weight management and type 2 diabetes in China) and survodutide (ongoing global phase 3 trials)—had potent weight‐loss and antihyperglycemic effects in people with obesity, with survodutide also improving liver health in people with MASH. Therefore, the research into glucagon physiology that led to glucagon receptor/GLP‐1 receptor dual agonists is translating to advantageous new therapies for the highly prevalent diseases of obesity and MASH.
- 11 October 2026
- Published by Wiley in Obesity Reviews
- p. e70228
The Power of Two: Harnessing Dual Glucagon and Incretin Signaling for Treatment of Obesity and Metabolic Dysfunction–Associated Steatohepatitis—A Narrative Review with a Translational Focus
A resurgence in glucagon research has repositioned this pancreatic hormone as a promising target in the treatment of obesity and related metabolic disorders. Glucagon is classically known for contributing to glucose homeostasis, but emerging evidence points to a much wider role in metabolism, including energy balance and liver health. These findings are fueling attempts to understand how to leverage glucagon signaling to treat obesity and metabolic dysfunction–associated steatohepatitis (MASH). Due to potential hyperglycemic effects of glucagon signaling, most investigational compounds are dual agonists of both the glucagon and glucagon‐like peptide‐1 (GLP‐1) receptors to harness the antihyperglycemic and anorectic effects of the latter hormone, analogs of which such as semaglutide are already proven to be potent obesity medications. Glucagon receptor/GLP‐1 receptor dual agonists reduce food intake, decrease hepatic fat, and increase energy expenditure in animal models of obesity and MASH. In early clinical trials, some dual agonists substantially reduced body weight, hepatic steatosis, and hepatic fibrosis. Whether they are more effective than GLP‐1 receptor mono‐agonists remains to be established in definitive head‐to‐head studies. The precise balance between glucagon and GLP‐1 signaling within individual compounds appears important for overall therapeutic effects—including glycemic control, which worsened with some dual agonists. However, the two most clinically advanced compounds—mazdutide (approved for chronic weight management and type 2 diabetes in China) and survodutide (ongoing global phase 3 trials)—had potent weight‐loss and antihyperglycemic effects in people with obesity, with survodutide also improving liver health in people with MASH. Therefore, the research into glucagon physiology that led to glucagon receptor/GLP‐1 receptor dual agonists is translating to advantageous new therapies for the highly prevalent diseases of obesity and MASH.
- Open Access
- 8 October 2026
- Published by Springer Nature in Obesity Surgery
- p. 1-8
Long-Term Satisfaction with the Choice to Complete Metabolic and Bariatric Surgery: The Hindsight 20/20 Study
- 8 October 2026
- Published by Springer Nature in Obesity Surgery
- p. 1-8
Open AccessLong-Term Satisfaction with the Choice to Complete Metabolic and Bariatric Surgery: The Hindsight 20/20 Study
- Open Access
- 7 October 2026
- Published by Wiley in Obesity Science & Practice
- Vol. 12 (5) , e70194
Preventing Weight Regain After Glucagon‐Like Peptide‑1 Therapy Discontinuation: A Pilot Randomized Controlled Trial
Objective: Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are effective treatments for obesity, but discontinuation is common due to cost, insurance coverage limitations, side effects, patient preference, and other factors. Weight regain often occurs rapidly after cessation, yet few evidence‐based strategies exist to support weight maintenance during this transition. This pilot randomized trial examined whether a digital wellness application or medically tailored meals (MTM) could mitigate weight gain during the first 4 months after GLP‐1 cessation. Methods: In this pilot randomized trial, adults with prior GLP‐1‐induced weight loss were randomized to usual care, wellness application, or MTM at the time of GLP‐1 cessation. Surveys assessed adherence and satisfaction (primary outcome) as well as exploratory outcomes, diet quality, and perceived health. Weight (exploratory) was measured monthly using validated Bluetooth scales. Results: Participants ( n = 39) were randomized to control ( N = 14), digital wellness application ( N = 12), or MTM ( N = 13) and had a mean baseline BMI 31.4 (SD 6.3) kg/m 2 . Diet quality, perceived health, adherence, and satisfaction did not significantly differ by group, though some estimates suggested possible trends favoring the wellness application. Relative to control, both the wellness application and MTM groups had less total weight gain: Wellness application −7.16% (95% CI: −12.27, −2.04) and MTM −7.17% (−12.20, −2.14). Conclusions: These findings suggest that structured support may attenuate early weight gain after GLP‐1 cessation. Larger, more diverse trials with longer follow‐up and clinical outcomes are needed to confirm results and clarify mechanisms.
- 7 October 2026
- Published by Wiley in Obesity Science & Practice
- Vol. 12 (5) , e70194
Open AccessPreventing Weight Regain After Glucagon‐Like Peptide‑1 Therapy Discontinuation: A Pilot Randomized Controlled Trial
Objective: Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are effective treatments for obesity, but discontinuation is common due to cost, insurance coverage limitations, side effects, patient preference, and other factors. Weight regain often occurs rapidly after cessation, yet few evidence‐based strategies exist to support weight maintenance during this transition. This pilot randomized trial examined whether a digital wellness application or medically tailored meals (MTM) could mitigate weight gain during the first 4 months after GLP‐1 cessation. Methods: In this pilot randomized trial, adults with prior GLP‐1‐induced weight loss were randomized to usual care, wellness application, or MTM at the time of GLP‐1 cessation. Surveys assessed adherence and satisfaction (primary outcome) as well as exploratory outcomes, diet quality, and perceived health. Weight (exploratory) was measured monthly using validated Bluetooth scales. Results: Participants ( n = 39) were randomized to control ( N = 14), digital wellness application ( N = 12), or MTM ( N = 13) and had a mean baseline BMI 31.4 (SD 6.3) kg/m 2 . Diet quality, perceived health, adherence, and satisfaction did not significantly differ by group, though some estimates suggested possible trends favoring the wellness application. Relative to control, both the wellness application and MTM groups had less total weight gain: Wellness application −7.16% (95% CI: −12.27, −2.04) and MTM −7.17% (−12.20, −2.14). Conclusions: These findings suggest that structured support may attenuate early weight gain after GLP‐1 cessation. Larger, more diverse trials with longer follow‐up and clinical outcomes are needed to confirm results and clarify mechanisms.
- Open Access
- 29 September 2026
- Published by Springer Nature in Obesity Surgery
- Vol. 36 (11) , 5864-5869
Trends in Metabolic and Bariatric Surgery Procedure Volume Recorded in MBSAQIP, 2015–2024
- 29 September 2026
- Published by Springer Nature in Obesity Surgery
- Vol. 36 (11) , 5864-5869
Open AccessTrends in Metabolic and Bariatric Surgery Procedure Volume Recorded in MBSAQIP, 2015–2024
- Open Access
- 17 September 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (12) , 11485-11495
Preferences for Obesity Medications Among People With Overweight or Obesity in the United States: A Discrete‐Choice Experiment ( OPTIC )
Aims: To evaluate the relative importance of attributes driving obesity medication (OM) choice and preferences among individuals with overweight or obesity. Materials and Methods: US adults with obesity or overweight and ≥ 1 obesity‐related complication completed an online survey including a discrete‐choice experiment (DCE) in October–November 2025. In the DCE, participants chose between 2 hypothetical, experimentally designed OM profiles with attributes/levels related to efficacy, cardiovascular (CV) risk reduction, side effects, administration (route/frequency), and dosing instruction requirements. In a fixed‐choice comparison, participants chose between 2 predefined oral OM profiles. Relative preference weights for the DCE attribute levels were estimated using a random‐parameters logit model to estimate attribute importance, tradeoffs, and predicted treatment choice. Results: Among 800 participants (400 OM‐naïve/400 OM‐experienced, 400 injection‐naïve/400 injection‐experienced), the most important attributes were route of administration, average weight‐loss percentage, CV risk reduction, and the proportion of people achieving ≥ 20% weight loss. Dosing instructions had the lowest relative importance. There was a preference for 1 OM profile (Treatment A—a hypothetical oral semaglutide‐like profile) over the alternative OM profile (Treatment B—a hypothetical orforglipron‐like profile), according to the responses from the DCE (84.2% vs. 15.8%) and the fixed‐choice question (90.0% vs. 10.0%). Only 23.4% indicated that taking an OM treatment on an empty stomach and waiting 30 min to eat would be disruptive to their lives. Most (73.3%) OM‐naïve participants were open to taking an oral OM. Conclusions: Individuals with overweight or obesity prioritise weight‐loss efficacy, CV risk reduction, and oral administration in OM treatment decisions; dosing instruction requirements were of low importance.
- 17 September 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (12) , 11485-11495
Open AccessPreferences for Obesity Medications Among People With Overweight or Obesity in the United States: A Discrete‐Choice Experiment ( OPTIC )
Aims: To evaluate the relative importance of attributes driving obesity medication (OM) choice and preferences among individuals with overweight or obesity. Materials and Methods: US adults with obesity or overweight and ≥ 1 obesity‐related complication completed an online survey including a discrete‐choice experiment (DCE) in October–November 2025. In the DCE, participants chose between 2 hypothetical, experimentally designed OM profiles with attributes/levels related to efficacy, cardiovascular (CV) risk reduction, side effects, administration (route/frequency), and dosing instruction requirements. In a fixed‐choice comparison, participants chose between 2 predefined oral OM profiles. Relative preference weights for the DCE attribute levels were estimated using a random‐parameters logit model to estimate attribute importance, tradeoffs, and predicted treatment choice. Results: Among 800 participants (400 OM‐naïve/400 OM‐experienced, 400 injection‐naïve/400 injection‐experienced), the most important attributes were route of administration, average weight‐loss percentage, CV risk reduction, and the proportion of people achieving ≥ 20% weight loss. Dosing instructions had the lowest relative importance. There was a preference for 1 OM profile (Treatment A—a hypothetical oral semaglutide‐like profile) over the alternative OM profile (Treatment B—a hypothetical orforglipron‐like profile), according to the responses from the DCE (84.2% vs. 15.8%) and the fixed‐choice question (90.0% vs. 10.0%). Only 23.4% indicated that taking an OM treatment on an empty stomach and waiting 30 min to eat would be disruptive to their lives. Most (73.3%) OM‐naïve participants were open to taking an oral OM. Conclusions: Individuals with overweight or obesity prioritise weight‐loss efficacy, CV risk reduction, and oral administration in OM treatment decisions; dosing instruction requirements were of low importance.
- Open Access
- 21 July 2026
- Published by Springer Nature in Obesity Surgery
- Vol. 36 (9) , 4720-4731
Association Between Delayed Metabolic and Bariatric Surgery Completion and Postoperative Cardiometabolic Outcomes
- 21 July 2026
- Published by Springer Nature in Obesity Surgery
- Vol. 36 (9) , 4720-4731
Open AccessAssociation Between Delayed Metabolic and Bariatric Surgery Completion and Postoperative Cardiometabolic Outcomes
- Open Access
- 8 July 2026
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 25 (2)
Discordance between adiposity and FIB-4 risk classification in US adults
Purpose: The fibrosis-4 index (FIB-4) is a widely used noninvasive tool for fibrosis risk stratification, however, the relationship between adiposity and FIB-4-based risk classification remains unclear. We evaluated the associations between multiple measurements of adiposity and FIB-4 risk classification in a nationally representative sample of U.S. adults. Methods: We analyzed data from 10,711 adults aged 35–65 years from the 2011–2018 NHANES. Examined anthropometric measures included body mass index (BMI), total body fat percentage (TBFP), waist circumference (WC), and waist-to-hip ratio (WH). We conducted logistic regression models to evaluate the association between anthropometric measurements and high-risk FIB-4 classification and to assess whether these associations differed by age group. Results: Most participants had low-risk FIB-4 scores (72.9%), followed by intermediate-risk (25.1%) and high-risk (2%). Individuals with low FIB-4 risk classification had higher BMI, TBFP and WC ( p < 0.01). In interaction models, the inverse associations between adiposity measures and high-risk FIB-4 classifications varied by age group. Among adults aged 51–65 years, higher BMI and TBFP were associated with lower odds of high-risk FIB-4 classification, whereas these associations were not significant for adults aged 35–50 years. Conclusion: Higher adiposity was associated with lower likelihood of high-risk FIB-4 classification. Age-stratified analyses suggested a potential discordance in the association between adiposity and FIB-4 risk classification across age groups. These findings suggest a potential discordance between adiposity-related metabolic risk and FIB-4-based risk classification, suggesting the need for age- and adiposity-informed risk assessment strategies for individuals at risk for hepatic fibrosis.
- 8 July 2026
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 25 (2)
Open AccessDiscordance between adiposity and FIB-4 risk classification in US adults
Purpose: The fibrosis-4 index (FIB-4) is a widely used noninvasive tool for fibrosis risk stratification, however, the relationship between adiposity and FIB-4-based risk classification remains unclear. We evaluated the associations between multiple measurements of adiposity and FIB-4 risk classification in a nationally representative sample of U.S. adults. Methods: We analyzed data from 10,711 adults aged 35–65 years from the 2011–2018 NHANES. Examined anthropometric measures included body mass index (BMI), total body fat percentage (TBFP), waist circumference (WC), and waist-to-hip ratio (WH). We conducted logistic regression models to evaluate the association between anthropometric measurements and high-risk FIB-4 classification and to assess whether these associations differed by age group. Results: Most participants had low-risk FIB-4 scores (72.9%), followed by intermediate-risk (25.1%) and high-risk (2%). Individuals with low FIB-4 risk classification had higher BMI, TBFP and WC ( p < 0.01). In interaction models, the inverse associations between adiposity measures and high-risk FIB-4 classifications varied by age group. Among adults aged 51–65 years, higher BMI and TBFP were associated with lower odds of high-risk FIB-4 classification, whereas these associations were not significant for adults aged 35–50 years. Conclusion: Higher adiposity was associated with lower likelihood of high-risk FIB-4 classification. Age-stratified analyses suggested a potential discordance in the association between adiposity and FIB-4 risk classification across age groups. These findings suggest a potential discordance between adiposity-related metabolic risk and FIB-4-based risk classification, suggesting the need for age- and adiposity-informed risk assessment strategies for individuals at risk for hepatic fibrosis.
- Open Access
Cardiovascular Disease and Obesity Medications in Older Women by Obesity‐Related Cancers Status: SEER ‐Medicare 2007–2015
Objective: This study evaluated the association between antiobesity medications (AOM) and incident cardiovascular disease (CVD) among older women, examining this relationship within and across survivors of obesity‐related cancers (ORCa) and age‐matched cancer‐free populations. Methods: We conducted a retrospective cohort study using SEER–Medicare data from 2007 to 2015. The study included 46,552 women aged ≥ 65 years: ORCa survivors ( n = 23,276) and age‐ and index‐matched cancer‐free women ( n = 23,276). Prediagnostic AOM prescriptions before CVD onset were examined using intent‐to‐treat (ITT) and per‐protocol approaches. Multivariable Cox proportional hazards models estimated hazard ratios (HR) and 95% CI for incident CVD. Results: In ITT analyses, AOM use was associated with lower CVD incidence in the composite analytic sample (HR = 0.80, 95% CI: 0.71–0.90) and among cancer‐free women (HR = 0.70, 95% CI: 0.58–0.85). Among ORCa survivors, estimates suggested a similar direction but were not statistically significant. In per‐protocol analyses, AOM use was associated with reduced CVD risk in ORCa survivors (HR = 0.74, 95% CI: 0.57–0.94) and cancer‐free women (HR = 0.59, 95% CI: 0.45–0.77). These associations were more pronounced within the first 2 years of follow‐up. Conclusions: AOM use was inversely associated with incident CVD among ORCa survivors and cancer‐free women. Further studies of second‐generation AOM, particularly glucagon‐like peptide‐1 receptor agonists, are warranted.
Open AccessCardiovascular Disease and Obesity Medications in Older Women by Obesity‐Related Cancers Status: SEER ‐Medicare 2007–2015
Objective: This study evaluated the association between antiobesity medications (AOM) and incident cardiovascular disease (CVD) among older women, examining this relationship within and across survivors of obesity‐related cancers (ORCa) and age‐matched cancer‐free populations. Methods: We conducted a retrospective cohort study using SEER–Medicare data from 2007 to 2015. The study included 46,552 women aged ≥ 65 years: ORCa survivors ( n = 23,276) and age‐ and index‐matched cancer‐free women ( n = 23,276). Prediagnostic AOM prescriptions before CVD onset were examined using intent‐to‐treat (ITT) and per‐protocol approaches. Multivariable Cox proportional hazards models estimated hazard ratios (HR) and 95% CI for incident CVD. Results: In ITT analyses, AOM use was associated with lower CVD incidence in the composite analytic sample (HR = 0.80, 95% CI: 0.71–0.90) and among cancer‐free women (HR = 0.70, 95% CI: 0.58–0.85). Among ORCa survivors, estimates suggested a similar direction but were not statistically significant. In per‐protocol analyses, AOM use was associated with reduced CVD risk in ORCa survivors (HR = 0.74, 95% CI: 0.57–0.94) and cancer‐free women (HR = 0.59, 95% CI: 0.45–0.77). These associations were more pronounced within the first 2 years of follow‐up. Conclusions: AOM use was inversely associated with incident CVD among ORCa survivors and cancer‐free women. Further studies of second‐generation AOM, particularly glucagon‐like peptide‐1 receptor agonists, are warranted.